The Medicines Company Announces Positive CHMP Opinion For Angiox(R) For Use In Heart Attack Patients Undergoing Emergency Heart Procedures

The Medicines Company (NASDAQ:MDCO) announced that the Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion applicable to all Member States of the European Union/European Economic Area that will extend the use of Angiox (bivalirudin) to include patients with heart attacks (so-called ST segment elevation myocardial infarction (STEMI)) undergoing emergency heart procedures called primary percutaneous coronary intervention (PCI).